報價延遲最少15分鐘:2026/08/26 09:50 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
22.7 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.49/0.75
|
|
企業價值
6.55B
|
| 資產負債 |
|
每股賬面淨值
6.63
|
| 現金流量 |
|
現金流量率
0.05
|
| 損益表 |
|
收益
1.19B
|
|
每股收益
4.10
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America. |
